VADUZ, Liechtenstein, Dec. 19, 2024 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the unique device RefluxStop for the treatment of acid reflux, a treatment field with 1 billion sufferers, announces that the leading Universitätsklinik Magdeburg, which is an INEK reporting hospital, now performs the RefluxStop procedure.
Earlier this month Prof. Dr. med. Frank Benedix and Dr. med. Steffi Peglow performed the first RefluxStop procedures at the Universitätsklinik Magdeburg. The university hospital has over 25 specialized departments and this state-of-the-art facility offers interdisciplinary consultation for patients with reflux disease. Since this center reports to the governmental body INEK on the actual costs for the procedure, this is one of an important group of hospitals when coming closer to reimbursement in Germany and part of an increasing number of INEK reporting centers using RefluxStop.
Prof. Dr. med. Frank Benedix, says, "I am very excited to be able to offer my patients the latest innovative technology in the surgical treatment of GERD, which has already helped several hundreds of patients in Germany and over 1000 patients across Europe. RefluxStop's long-term outcomes look very promising and offer access to an additional surgical option for previously untreatable patients and countless more GERD patients who struggle with the relentless and painful symptoms of the disease on a daily basis."
The CEO and founder of Implantica and inventor of RefluxStop, Dr. Peter Forsell, says, "We are filled with energy and enthusiasm to partner with the additional key figures in the surgical treatment field of GERD, Prof. Dr. med. Frank Benedix and Dr. med. Steffi Peglow, at the prestigious Universitätsklinik Magdeburg. With about 17% of the German population suffering from GERD, the impact on people's lives, including the socio-economic impact, is often hugely underestimated. One study estimates that work absences due to GERD alone result in a loss of well over €600 million each year.¹ I believe innovations like RefluxStop have the potential to revolutionize patient outcomes for millions of GERD patients and ultimately, in line with our company's mission, save tremendous costs for society!"
- Leodolter A, Nocon M, Kulig M, Willich SN, Malfertheiner P, Labenz J. Gastro esophageal reflux disease is associated with absence from work: results from a prospective cohort study. World J Gastroenterol. 2005 Dec 7;11(45):7148-51. doi: 10.3748/wjg.v11.i45.7148. PMID: 16437662; PMCID: PMC4725079.
For further information, please contact:
Nicole Pehrsson, Chief Corporate Affairs Officer
Telephone (CH): +41 (0)79 335 09 49
nicole.pehrsson@implantica.com
Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.
The company's Certified Adviser is FNCA Sweden AB, info@fnca.se
The information was sent for publication, through the agency of the contact person set out above, on December 19, 2024, at 08:30 a.m. (CET).
About Implantica
Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica's lead product, RefluxStop, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energizing platform designed to power remote-controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit www.implantica.com for further information.
About RefluxStop
RefluxStop is a new innovative treatment that has the potential to spur a paradigm shift in anti-reflux surgery. It's unique mechanism of action differentiates it from standard of care and current surgical solutions. Longer established surgical options for GORD involve encircling the food passageway to support the lower oesophageal sphincter's closing mechanism and are commonly associated with side effects such as swallowing difficulties, pain when swallowing and inability to belch and/or vomit.
In contrast, the RefluxStop device treats the cause of acid reflux without encircling and putting pressure on the food passageway. It restores and maintains the lower oesophageal sphincter in its original, natural position.
The RefluxStop mechanism of action is focused on reconstructing all three components of the anti-reflux barrier, that if compromised could possibly result in acid reflux. It restores and supports the natural anatomical physiology of the body allowing the body to itself solve the problem with acid reflux.
Newsroom
https://www.implantica.com/media/media-kit
Community
https://ch.linkedin.com/company/implantica
https://www.twitter.com/implantica
Media Contact:
Implantica AG
Juanita Eberhart, VP Marketing & Advocacy
M: +1 925-381-4581
juanita.eberhart@implantica.com
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/implantica/r/implantica-strengthens-the-strategic-refluxstop--expansion-with-the-addition-of-yet-another-key-univ,c4084661
The following files are available for download:
https://mb.cision.com/Main/19732/4084661/3182581.pdf | Implantica strengthens the strategic RefluxStop' expansion with the addition of yet another key University Hospital in Germany with several more in the pipeline |
https://news.cision.com/implantica/i/logo-transparent-1-8,c3364590 | logo transparent 1 8 |
https://news.cision.com/implantica/i/reluxstop-product,c3364591 | ReluxStop Product |
View original content:https://www.prnewswire.co.uk/news-releases/implantica-strengthens-the-strategic-refluxstop-expansion-with-the-addition-of-yet-another-key-university-hospital-in-germany-with-several-more-in-the-pipeline-302335985.html
